These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 11183927)

  • 1. Stats & facts. Prostate cancer in the gender-specific scheme of things.
    Manag Care Interface; 2000 Jul; 13(7):38-9. PubMed ID: 11183927
    [No Abstract]   [Full Text] [Related]  

  • 2. Prostate cancer and prostate-specific antigen: facts, figures and commentary.
    Chambers DC
    J Insur Med; 1993; 25(3):336-40. PubMed ID: 10146433
    [No Abstract]   [Full Text] [Related]  

  • 3. Prostate cancer options expand beyond the PSA.
    Clin Resour Manag; 2002 May; 3(5):65-8. PubMed ID: 12048767
    [No Abstract]   [Full Text] [Related]  

  • 4. Prostate cancer mortality rates compared to urologist population densities and prostate-specific antigen screening levels on a state-by-state basis in the United States of America.
    Colli JL; Amling CL
    Prostate Cancer Prostatic Dis; 2008; 11(3):247-51. PubMed ID: 18268527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regular PSA screens undervalued, underutilized in prostate cancer detection.
    Healthc Demand Dis Manag; 2000 May; 6(5):70-2, 65. PubMed ID: 11383016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stats & Facts. Prostate-specific antigen screening.
    Manag Care Interface; 2001 Jul; 14(7):40-1. PubMed ID: 11481814
    [No Abstract]   [Full Text] [Related]  

  • 7. No one dies from prostate cancer?
    Chau D
    Arch Intern Med; 2006 Jul; 166(14):1525; author reply 1526. PubMed ID: 16864764
    [No Abstract]   [Full Text] [Related]  

  • 8. [Detection of prostate cancer: yes or no?].
    Van Cangh PJ
    Bull Mem Acad R Med Belg; 2006; 161(3-4):159-69. PubMed ID: 17172224
    [No Abstract]   [Full Text] [Related]  

  • 9. Prostate cancer screening; is this a teachable moment?
    Brawley OW
    J Natl Cancer Inst; 2009 Oct; 101(19):1295-7. PubMed ID: 19720970
    [No Abstract]   [Full Text] [Related]  

  • 10. Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?
    Barry MJ; Mulley AJ
    J Natl Cancer Inst; 2009 Mar; 101(6):362-3. PubMed ID: 19276451
    [No Abstract]   [Full Text] [Related]  

  • 11. Prostate cancer: is the PSA test the answer?
    Berlin B
    N J Med; 1998 Mar; 95(3):53-5. PubMed ID: 16013148
    [No Abstract]   [Full Text] [Related]  

  • 12. Assessing risk: does this patient have prostate cancer?
    Carter HB
    J Natl Cancer Inst; 2006 Apr; 98(8):506-7. PubMed ID: 16622114
    [No Abstract]   [Full Text] [Related]  

  • 13. Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: an analysis of Radiation Therapy Oncology Group Protocol 92-02.
    Valicenti RK; DeSilvio M; Hanks GE; Porter A; Brereton H; Rosenthal SA; Shipley WU; Sandler HM;
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1064-71. PubMed ID: 16979837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate priorities: a new approach to the cancer that 1 in 6 American men will eventually get.
    Gupta S
    Time; 2004 Oct; 164(14):90. PubMed ID: 15503786
    [No Abstract]   [Full Text] [Related]  

  • 15. Prostate-specific antigen levels in the United States: implications of various definitions for abnormal.
    Welch HG; Schwartz LM; Woloshin S
    J Natl Cancer Inst; 2005 Aug; 97(15):1132-7. PubMed ID: 16077071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening by prostate-specific antigen and digital rectal examination in relation to prostate cancer mortality. A case-control study.
    Walsh PC
    J Urol; 2005 Nov; 174(5):1824-5. PubMed ID: 16217296
    [No Abstract]   [Full Text] [Related]  

  • 17. Prostate-specific antigen levels, prostate-specific antigen kinetics, and prostate cancer prognosis: a tocsin calling for prospective studies.
    Parekh DJ; Ankerst DP; Thompson IM
    J Natl Cancer Inst; 2007 Apr; 99(7):496-7. PubMed ID: 17405989
    [No Abstract]   [Full Text] [Related]  

  • 18. Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends.
    Telesca D; Etzioni R; Gulati R
    Biometrics; 2008 Mar; 64(1):10-9. PubMed ID: 17501937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What is the value of screening for prostate cancer in the US?
    Albertsen PC
    Nat Clin Pract Oncol; 2005 Nov; 2(11):536-7. PubMed ID: 16270077
    [No Abstract]   [Full Text] [Related]  

  • 20. Prostate specific antigen screening.
    Block KI
    Integr Cancer Ther; 2009 Jun; 8(2):111-2. PubMed ID: 19679618
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.